Table 4.
Threshold effect analyses of TyG index on the risk of DKD in patients with T2D.
| TyG index | Non-adjusted | Adjust A | Adjust B | |||
|---|---|---|---|---|---|---|
| OR (95%CI) | P | OR (95%CI) | P | OR (95%CI) | P | |
| Categorical | ||||||
| ≦ 9.35 | Ref. | Ref. | Ref. | |||
| > 9.35 | 1.45 (1.08 - 1.94) | 0.012 | 1.89 (1.36 - 2.63) | < 0.001 | 1.85 (1.28 - 2.64) | < 0.001 |
| Continuous | ||||||
| ≦ 9.35 | 0.91 (0.62 - 1.34) | 0.634 | 1.05 (0.69 - 1.61) | 0.811 | 0.98 (0.61 - 1.58) | 0.941 |
| > 9.35 | 1.50 (0.94 - 2.39) | 0.087 | 2.04 (1.19 - 3.50) | 0.010 | 1.94 (1.10 - 3.43) | 0.022 |
Adjust A was adjusted for age, gender, hypertension, diabetic duration, and ACEI/ARB usage; Adjust B was adjusted for age, gender, hypertension, diabetic duration, ACEI/ARB usage, HbA1c, HDL-C, and LDL-C. DKD, diabetic kidney disease; TyG, triglyceride glucose; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HbA1c, glycated hemoglobin; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; OR, odds ratio; T2D, type 2 diabetes.